AIM Bio

AIM Bio is a South Korean biotechnology company specializing in the development of next-generation antibody-drug conjugates (ADCs) and bispecific antibodies, with a specific focus on central nervous system (CNS) disorders and oncology. Spun off from the Samsung Medical Center and KAIST, the company utilizes its proprietary B-IND platform to engineer therapies capable of crossing the blood-brain barrier (BBB) to treat aggressive brain cancers like glioblastoma. Their lead programs target B7-H3 and other validated tumor antigens to deliver potent payloads directly to intracranial tumors while minimizing systemic toxicity. AIM Bio's approach combines advanced antibody engineering with specialized linker-payload technologies to address high unmet needs in neuro-oncology. The company leverages a vast library of patient-derived cells to validate targets and optimize its therapeutic candidates for clinical success. By focusing on the unique challenges of brain tumor treatment, AIM Bio aims to provide transformative options for patients with refractory cancers.